Chinese Firms Expand Solo Global Phase III Activity Including US Sites
Indicative Of Independent Growth
Throughout 2024, Chinese firms as sole sponsors initiated a total of seven global Phase III trials that including US sites. BeiGene, Genfleet and InnoCare are expected to add four similar studies this year.
